Nothing Special   »   [go: up one dir, main page]

FR2844716A1 - Synergistic composition for hygiene and prophylactic treatment of feet of diabetics, comprising anti-dehydration agent, microcirculation modulator and antiseptic - Google Patents

Synergistic composition for hygiene and prophylactic treatment of feet of diabetics, comprising anti-dehydration agent, microcirculation modulator and antiseptic Download PDF

Info

Publication number
FR2844716A1
FR2844716A1 FR0211712A FR0211712A FR2844716A1 FR 2844716 A1 FR2844716 A1 FR 2844716A1 FR 0211712 A FR0211712 A FR 0211712A FR 0211712 A FR0211712 A FR 0211712A FR 2844716 A1 FR2844716 A1 FR 2844716A1
Authority
FR
France
Prior art keywords
pharmaceutical compositions
compositions according
agent
diabetics
hygiene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR0211712A
Other languages
French (fr)
Other versions
FR2844716B3 (en
FR2844716B1 (en
Inventor
Marcel Jacques Chicouri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to FR0211712A priority Critical patent/FR2844716B1/en
Publication of FR2844716A1 publication Critical patent/FR2844716A1/en
Publication of FR2844716B3 publication Critical patent/FR2844716B3/en
Application granted granted Critical
Publication of FR2844716B1 publication Critical patent/FR2844716B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Pharmaceutical compositions (A) for the hygiene and prophylactic treatment of the feet of diabetics to prevent cutaneous incidents and/or accidents contain a synergistic combination of a first agent (I) for combating dermal/epidermal dehydration, a second agent (II) acting on microcirculation in the dermal/epidermal blood vessels and a third agent (III) having antiseptic activity.

Description

NOUVELLES COMPOSITIONS PHARMACEUTIQUES DESTINEES NOTAMMENT A L'HYGIENE DESNEW PHARMACEUTICAL COMPOSITIONS INTENDED IN PARTICULAR FOR HYGIENE OF

PIEDS DES DIABETIQUESDIABETIC FEET

L'invention se rapporte au domaine de la chimie et en particulier à celui de la chimie thérapeutique. Elle a plus particulièrement pour objet de nouvelles compositions pharmaceutiques présentées notamment pour l'usage topique, nuvelles compositions pharmaceutiques destinées notamment à l'hygiène et à la prophylaxie des pieds des diabétiques. 10 Elle se rapporte précisément à des compositions dermatologiques destinées à traiter ou à prévenir les incidents ou les accidents cutanés liés à la survenue de lésions dénommées pied diabétique. Le diabète est une affection atteignant un nombre de plus en plus grand de sujets de par le monde. Ce nombre croissant émeut à juste titre les autorités médicales et gouvernementales mondiales.  The invention relates to the field of chemistry and in particular to that of therapeutic chemistry. It relates more particularly to new pharmaceutical compositions presented in particular for topical use, new pharmaceutical compositions intended in particular for the hygiene and prophylaxis of the feet of diabetics. 10 It relates specifically to dermatological compositions intended to treat or prevent incidents or skin accidents linked to the occurrence of lesions called diabetic foot. Diabetes is a condition that affects more and more people around the world. This growing number rightly moves the world's medical and government authorities.

L'OMS dénombre actuellement 150 millions de diabétiques dans le monde; ce nombre sera 20 probablement doublé dans deux décennies.  WHO currently has 150 million diabetics worldwide; that number will likely double in two decades.

En France, on relève près de 3 millions de diabétiques dont 800.000 ignorent leur état.  In France, there are nearly 3 million diabetics, 800,000 of whom are unaware of their condition.

On sait que les conséquences du diabète sont essentiellement des affections liées à des 25 troubles de la micro- et/ou de la macrocirculation, responsables de la morbidité de la maladie diabétique. Liées à la micro-circulation sont les atteintes rénales, oculaires, cardiaques, cérébrales. Liées à la macro-circulation, sont les atteintes artéritiques des gros vaisseaux  It is known that the consequences of diabetes are essentially conditions linked to micro- and / or macrocirculation disorders responsible for the morbidity of diabetic disease. Linked to micro-circulation are kidney, eye, heart and brain damage. Linked to macro-circulation, are arteritic lesions of the large vessels

aorte, artères des membres inférieurs distales et/ou proximales.  aorta, arteries of the distal and / or proximal lower limbs.

L'artérite des pieds est un risque majeur chez le diabétique qui conduirait à 10.000 amputations par an. La vulnérabilité du pied diabétique a pour cause une double atteinte  Arteritis of the feet is a major risk in diabetics which would lead to 10,000 amputations per year. The vulnerability of the diabetic foot is due to a double attack

possible artérielle et neuropathique.  possible arterial and neuropathic.

En effet, sur une zone agressée; blessée, infection: oedème, inflammation, infection surviennent facilement chez les diabétiques. De tels incidents requièrent une irrigation suffisante, ce que ne peuvent apporter des artères rétrécies au flux sanguin insuffisant. Ajouté à cela, le manque de sensibilité régionale occasionnée par une neuropathie d'un patient 5 diabétique qui ne ressent pas la douleur et qui ne réaliserait pas même la présence d'une plaie éventuelle.  Indeed, on an attacked area; injured, infection: edema, inflammation, infection occur easily in diabetics. Such incidents require sufficient irrigation, which cannot be done by narrowed arteries with insufficient blood flow. Added to this, the lack of regional sensitivity caused by neuropathy of a diabetic patient who does not feel pain and who would not even realize the presence of a possible wound.

On comprend ainsi l'extrême importance à titre prophylactique d'une hygiène rigoureuse du pied. Cette hygiène doit viser à se prémunir contre une atteinte microbienne ou mycosique, 10 elle vise en même temps au maintien d'une intégrité dermo-épidermique constante à titre prophylactique. Cette prophylaxie commence par la recommandation d'un lavage rigoureux des pieds, suivi d'un séchage soigné. De plus, il faut lutter contre les phénomènes possibles de déshydratation cutanée, plus fréquents qu'à l'inverse d'une dyshydrose, ces phénomènes pouvant constituer un terrain propice à une quelconque infection. 15 C'est dans ce contexte que vient s'inscrire l'utilisation recommandée d'une préparation protectrice à visée prophylactique, qui tient compte des facteurs susceptibles d'être impliqués  We can therefore understand the extreme prophylactic importance of rigorous foot hygiene. This hygiene must aim to protect against microbial or mycotic damage, 10 it aims at the same time to maintain a constant dermo-epidermal integrity on a prophylactic basis. This prophylaxis begins with the recommendation of a rigorous washing of the feet, followed by careful drying. In addition, it is necessary to fight against the possible phenomena of cutaneous dehydration, more frequent than on the contrary of a dyshydrosis, these phenomena being able to constitute a favorable ground for any infection. 15 It is in this context that the recommended use of a protective preparation for prophylactic purposes comes into play, which takes into account the factors likely to be involved.

dans la survenue d'incidents ou d'accidents cutanés chez le pied du diabétique.  in the occurrence of incidents or skin accidents in the diabetic's foot.

La présente invention consiste donc en ce qu'on préconise à titre prophylactique une préparation dotée d'une triple activité synergique  The present invention therefore consists in that a prophylactic preparation is recommended having a triple synergistic activity

La première agit sur les phénomènes de déshydratation dermo-épidermique. La deuxième agit sur les phénomènes circulatoires capillaro-veineux. La troisième va avoir une activité 25 antiseptique en prévention des risques d'atteintes bactériennes et/ou mycosiques.  The first acts on the dermo-epidermal dehydration phenomena. The second acts on capillary-venous circulatory phenomena. The third will have an antiseptic activity in prevention of the risks of bacterial and / or mycotic attacks.

L'invention se rapporte donc à la réalisation de compositions pharmaceutiques concernant en premier lieu l'action favorisante sur l'hydratation dermo-épidermique, qui comporte au moins l'un des principes actifs suivants - l'hydantoine - le glycérol - les polyols l'hydroxypolysilane notamment associés en outre dans la formule à environ 40 % d'eau d'une source minérale reconnue pour son efficacité en dermatologie, comme par exemple l'eau d'Uriage, l'eau de Molitg-les-bains,  The invention therefore relates to the production of pharmaceutical compositions concerning in the first place the promoting action on the dermo-epidermal hydration, which comprises at least one of the following active principles - hydantoin - glycerol - polyols l hydroxypolysilane especially associated in addition in the formula with approximately 40% water from a mineral source recognized for its effectiveness in dermatology, such as for example Uriage water, Molitg-les-bains water,

l'eau de Dax, de Laroche Posay et d'Avène notamment.  the water of Dax, Laroche Posay and Avène in particular.

En ce qui concerne l'action vasculo-protectrice on incorpore encore dans les compositions selon l'invention un ou plusieurs des produits suivants: - les vitamines A et E - des anti-oxydants du type citroflavonodes - un extrait de Centella asiatica 10 - la Rutine... notamment En ce qui concerne l'action antiseptique, on incorpore aux compositions une ou des huiles essentielles aux actions bactéricides, bactériostatiques fongicides reconnues, et notamment, l'huile essentielle de Romarin, l'huile essentielle d'Origan, l'huile essentielle de Melaleuca et 15 l'huile essentielle de Lavande, et enfin en association une solution de gluconate de Zinc à  As regards the vasculo-protective action, one or more of the following products are also incorporated into the compositions according to the invention: - vitamins A and E - antioxidants of the citroflavonodes type - an extract of Centella asiatica 10 - the Rutin ... in particular As regards the antiseptic action, one or more essential oils are incorporated into the compositions with bactericidal, bacteriostatic fungicidal actions recognized, and in particular, essential oil of Rosemary, essential oil of Oregano, l essential oil of Melaleuca and essential oil of Lavender, and finally in combination with a solution of Zinc gluconate

%à10%.% To 10%.

Les compositions selon l'invention sont incorporées dans un excipient ou un véhicule inerte non allergisant adapté à l'usage dermatologique. 20  The compositions according to the invention are incorporated in an inert non-allergenic excipient or vehicle suitable for dermatological use. 20

4 28447164 2844716

Claims (7)

REVENDICATIONS l. Compositions pharmaceutiques destinées à l'hygiène et à la prophylaxie des pieds des diabétiques caractérisées par une triple association active synergiquenmelt en vue d'éviter incidents et/ou accidents cutanés.  l. Pharmaceutical compositions intended for the hygiene and prophylaxis of the feet of diabetics characterized by a triple synergistic active association in order to avoid skin incidents and / or accidents. Le premier agent est destiné à lutter contre les phénomènes de déshydratation dermoépidermiques.  The first agent is intended to fight against dermoepidermal dehydration phenomena. Le deuxième agent est destiné à agir sur la MNicrocirculation des vaisseaux dermoépidermiques.  The second agent is intended to act on the MNicrocirculation of the dermoepidermal vessels. Le troisième agent est un agent doté de propriétés antiseptiques.  The third agent is an agent with antiseptic properties. 2. Compositions pharmaceutiques selon la revendication 1, caractérisées en ce que les composants agissent sur les phénomènes de deshydratation dermo-épidermiques, ils appartiennent à la classe des substances hygroscopiques, hydratantes et humrnectantes, 1 5. ils ont pour propriétés de ralentir la vitesse d'évaporation de l'eau et de permettre alors  2. Pharmaceutical compositions according to claim 1, characterized in that the components act on the phenomena of dermo-epidermal dehydration, they belong to the class of hygroscopic, moisturizing and moisturizing substances, 1 5. they have the properties of slowing down the speed of water and then allow une imprégnation prolongée au Stratum Corneum.  prolonged impregnation at the Stratum Corneum. 3. Compositions pharmaceutiques suivant la revendication 1 ou la revendication 2, caractérisées en ce que le ou les composants favirisant l'hydratation denno20 épidermique sont choisis dans le groupe constitué par l'hydantone, le glycérot, les  3. Pharmaceutical compositions according to claim 1 or claim 2, characterized in that the component or components favoring epidermal hydration are chosen from the group consisting of hydantone, glycerot, polyols, I'hydroxyproline, l'urée.polyols, hydroxyproline, urea. 4. Compositions pharmaceutiques selon la revendication 1, caractérisé en ce que le  4. Pharmaceutical compositions according to claim 1, characterized in that the composant favorisant l'hydratation dermo-épidermique est associé à une eau minérale 25 de Source dont l'intérêt est reconnu en dermatologie.  component promoting dermo-epidermal hydration is associated with mineral water 25 from Source whose interest is recognized in dermatology. 5. Compositions pharmaceutiques selon la revendication 1, caractérisée en ce que le  5. Pharmaceutical compositions according to claim 1, characterized in that the deuxième constituant est un composé actif sur les phénomènes circulatoires capillaro veineux et particulièrement sur la stase veineuse lymphatique de la semelle veineuse 30 plantaire.  second constituent is a compound active on the capillary venous circulatory phenomena and particularly on the lymphatic venous stasis of the plantar venous sole. 6. Compositions pharmaceutiques selon la revendication 1, caractérisées en ce le troisième constituant est un composé à action antiseptique et de prévention des risques  6. Pharmaceutical compositions according to claim 1, characterized in that the third constituent is a compound with antiseptic action and risk prevention 28447162844716 d'atteintes bactéreimes et/ou mycosique; il est donc choisi parmi des huiles  bacterial and / or fungal damage; it is therefore chosen from oils essentielles traditionnelles utilisées dans ce domaine.  essentials used in this field. 7. Compositions pharmaceutiques selon la revendication 5, dans lesquelles les huiles 5 essentielles seront choisies dans la classe Botanique des Labièes, telles que P'H.E  7. Pharmaceutical compositions according to claim 5, in which the essential oils will be chosen from the Botanical class of Labies, such as P'H.E (huile essentielle) d'origan, de thym et de romarin.  (essential oil) of oregano, thyme and rosemary.
FR0211712A 2002-09-23 2002-09-23 NOVEL PHARMACEUTICAL COMPOSITIONS, IN PARTICULAR FOR FOOD HYGIENE OF DIABETICS Expired - Fee Related FR2844716B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR0211712A FR2844716B1 (en) 2002-09-23 2002-09-23 NOVEL PHARMACEUTICAL COMPOSITIONS, IN PARTICULAR FOR FOOD HYGIENE OF DIABETICS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0211712A FR2844716B1 (en) 2002-09-23 2002-09-23 NOVEL PHARMACEUTICAL COMPOSITIONS, IN PARTICULAR FOR FOOD HYGIENE OF DIABETICS

Publications (3)

Publication Number Publication Date
FR2844716A1 true FR2844716A1 (en) 2004-03-26
FR2844716B3 FR2844716B3 (en) 2004-10-29
FR2844716B1 FR2844716B1 (en) 2008-11-21

Family

ID=31970881

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0211712A Expired - Fee Related FR2844716B1 (en) 2002-09-23 2002-09-23 NOVEL PHARMACEUTICAL COMPOSITIONS, IN PARTICULAR FOR FOOD HYGIENE OF DIABETICS

Country Status (1)

Country Link
FR (1) FR2844716B1 (en)

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2315258A1 (en) * 1975-06-23 1977-01-21 Fisons Ltd Cosmetic cream for chapped and dry skin - including olive oil, liquid silicone, emulsifying wax, sequestrant, water and glycerol
DE3507791A1 (en) * 1984-03-07 1985-09-26 Roshdy Ismail Composition for protecting the skin
WO1998002138A1 (en) * 1996-07-12 1998-01-22 Indústria e Comércio de Cosméticos Natura Ltda. Desiccant composition, in emulsion form, for the skin
RU2112548C1 (en) * 1995-11-03 1998-06-10 Рязанский государственный медицинский университет им.акад.И.П.Павлова Preparation for suppurative wound treatment at diabetes mellitus background
WO1998051291A1 (en) * 1997-05-13 1998-11-19 Remacle Jose Use of a pharmaceutical composition for treating and/or preventing ischemia
US5869062A (en) * 1997-05-27 1999-02-09 Oliver; Benjamin Skin treatment composition
RU2146921C1 (en) * 1997-11-05 2000-03-27 Рязанский областной клинический кожно-венерологический диспансер Ointment composition stimulating epithelium regeneration
WO2001017484A2 (en) * 1999-09-07 2001-03-15 D.T.R. Dermal Therapy Research Inc. Topical urea composition
US20010005510A1 (en) * 1997-11-13 2001-06-28 Dona Garofano Anti-fungal composition
JP2001206832A (en) * 2000-01-25 2001-07-31 Kao Corp Cosmetic
WO2002047680A2 (en) * 2000-12-15 2002-06-20 Galileo Laboratories, Inc. Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia
WO2002049575A2 (en) * 2000-12-21 2002-06-27 The Quigley Corporation Method and composition for the treatment of diabetic neuropathy
JP2002212052A (en) * 2001-01-15 2002-07-31 Hajime Ito External preparation
WO2002058640A1 (en) * 2001-01-23 2002-08-01 Harris Dennis H Topical therapeutic skin care system

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2315258A1 (en) * 1975-06-23 1977-01-21 Fisons Ltd Cosmetic cream for chapped and dry skin - including olive oil, liquid silicone, emulsifying wax, sequestrant, water and glycerol
DE3507791A1 (en) * 1984-03-07 1985-09-26 Roshdy Ismail Composition for protecting the skin
RU2112548C1 (en) * 1995-11-03 1998-06-10 Рязанский государственный медицинский университет им.акад.И.П.Павлова Preparation for suppurative wound treatment at diabetes mellitus background
WO1998002138A1 (en) * 1996-07-12 1998-01-22 Indústria e Comércio de Cosméticos Natura Ltda. Desiccant composition, in emulsion form, for the skin
WO1998051291A1 (en) * 1997-05-13 1998-11-19 Remacle Jose Use of a pharmaceutical composition for treating and/or preventing ischemia
US5869062A (en) * 1997-05-27 1999-02-09 Oliver; Benjamin Skin treatment composition
RU2146921C1 (en) * 1997-11-05 2000-03-27 Рязанский областной клинический кожно-венерологический диспансер Ointment composition stimulating epithelium regeneration
US20010005510A1 (en) * 1997-11-13 2001-06-28 Dona Garofano Anti-fungal composition
WO2001017484A2 (en) * 1999-09-07 2001-03-15 D.T.R. Dermal Therapy Research Inc. Topical urea composition
JP2001206832A (en) * 2000-01-25 2001-07-31 Kao Corp Cosmetic
WO2002047680A2 (en) * 2000-12-15 2002-06-20 Galileo Laboratories, Inc. Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia
WO2002049575A2 (en) * 2000-12-21 2002-06-27 The Quigley Corporation Method and composition for the treatment of diabetic neuropathy
JP2002212052A (en) * 2001-01-15 2002-07-31 Hajime Ito External preparation
WO2002058640A1 (en) * 2001-01-23 2002-08-01 Harris Dennis H Topical therapeutic skin care system

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199952, Derwent World Patents Index; Class B05, AN 1999-608972, XP002376160 *
DATABASE WPI Section Ch Week 200059, Derwent World Patents Index; Class B05, AN 2000-617480, XP002376161 *
DATABASE WPI Section Ch Week 200279, Derwent World Patents Index; Class A96, AN 2002-726494, XP002376158 *
DORMAN H J D ET AL: "Antimicrobial agents from plants: Antibacterial activity of plant volatile oils", JOURNAL OF APPLIED MICROBIOLOGY, vol. 88, no. 2, February 2000 (2000-02-01), pages 308 - 316, XP008037266, ISSN: 1364-5072 *
ISCAN G ET AL: "Antimicrobial screening of mentha piperita essential oils", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 50, 2002, pages 3943 - 3946, XP002984318, ISSN: 0021-8561 *
MARINO MARILENA ET AL: "Impedance measurements to study the antimicrobial activity of essential oils from Lamiaceae and Compositae", INTERNATIONAL JOURNAL OF FOOD MICROBIOLOGY, vol. 67, no. 3, 5 August 2001 (2001-08-05), pages 187 - 195, XP007900385, ISSN: 0168-1605 *
MOELLER H ET AL: "WIRKUNGEN VON VITAMIN E AUF DIE HAUT BEI TOPISCHER ANWENDUNG", 1989, FETT WISSENSCHAFT TECHNOLOGIE- FAT SCIENCE TECHNOLOGY, CONRADIN INDUSTRIEVERLAG. LEINFELDEN ECHTERDINGEN, DE, PAGE(S) 295-305, ISSN: 0931-5985, XP002043320 *
PATENT ABSTRACTS OF JAPAN vol. 2000, no. 24 11 May 2001 (2001-05-11) *
PATTNAIK S ET AL: "ANTIBACTERIAL AND ANTIFUNGAL ACTIVITY OF AROMATIC CONSTITUENTS OF ESSENTIAL OILS", MICROBIOS, CAMBRIDGE, GB, vol. 89, no. 358, 1997, pages 39 - 46, XP008005194, ISSN: 0026-2633 *

Also Published As

Publication number Publication date
FR2844716B3 (en) 2004-10-29
FR2844716B1 (en) 2008-11-21

Similar Documents

Publication Publication Date Title
US20070253943A1 (en) Compositions for Topical Treatment
US20140287064A1 (en) Compositions for improving the appearance and/or treating fungal infections of nails, mucus membranes and the integument
US20110236503A1 (en) Topical Skincare Composition
FR2504551A1 (en) Compsn. for treating skin, e.g. burns, eczema or acne - contains essential oils from Labiatae and other plant families
US20080145461A1 (en) Formulation and method of making a topical pain relief composition
US5565189A (en) Wound cleanser method of use
FR2591109A1 (en) DRUG COMPOSITION BASED ON NATURAL OIL OF VEGETABLE ORIGIN FOR USE IN THE TREATMENT OF HERPES.
FR2791262A1 (en) COMPOSITIONS BASED ON CHONDROITINE AND CHITOSAN FOR THE PROTECTION, TREATMENT OR REPLACEMENT OF CONNECTIVE TISSUES
FR2844716A1 (en) Synergistic composition for hygiene and prophylactic treatment of feet of diabetics, comprising anti-dehydration agent, microcirculation modulator and antiseptic
EP2309981B1 (en) Dermatological composition for the treatment of scabs
FR2758724A1 (en) Controlling cellulite and fat deposition
CA1026188A (en) Antiseptic compound
EP3506876B1 (en) Composition for nail fungus
EP0391780B1 (en) Anti-itching composition
JP2017534689A (en) Methods for the prevention and treatment of acne
US20130034618A1 (en) Compositions for treating the integument
EP0884948B1 (en) Antiseptic compositions containing chlorobutanol and chlorhexidine
BE1015498A5 (en) COMPOSITION AND USE OF THE IODE PUR DISSOLVED IN ESSENTIAL OIL MELALEUCA alternifolia AND / OR MELALEUCA quinquinervia.
US20240269150A1 (en) Wound treatment composition
EP0225833A2 (en) Veterinary medicinal composition, particularly for the treatment of locomotory system diseases or for the preparation towards the effort and the recovery of, for example, sporting horses or hunting dogs especially sporting dogs
FR3127397A1 (en) Aqueous solution based on Syzygium aromaticum, method of preparation and associated uses
FR2725901A1 (en) Topical compsn. contg. calcium salt
FR2918278A1 (en) USE OF OLEOCANTHAL IN THE TREATMENT OF SKIN INFLAMMATION.
DE2906571A1 (en) Treatment of vascular disease - by deep intramuscular injection of aq. potassium permanganate soln.
FR2848114A1 (en) Cosmetic or dermatological composition used for genito-crural and perineo-gluteal hygiene, prophylaxis and therapy comprises hinokitiol

Legal Events

Date Code Title Description
RN Application for restoration
FC Decision of inpi director general to approve request for restoration
MV Notification of grant is cancelled

Free format text: BOPI DE PUBLICATION N: 04/44 PAGES: 211 PARTIE DU BULLETIN CONCERNEE: BREVETS D'INVENTION, CERTIFICATS D'UTILITE, CERTIFICATS D'ADDITION DELIVRES NATURE DU TITRE ET N: CERTIFICAT D'UTILITE N 2844716 IL Y A LIEU DE SUPPRIMER: LA DECISION DE DELIVRANCE DU CERTIFICAT D UTILITE A ETE RAPPORTEE. EN CONSEQUENCE LA MENTION DE DELIVRANCE PUBLIEE AU BOPI 04/44 DOIT ETRE TENUE POUR NULLE ET NON AVENUE LA PROCEDURE DE DELIVRANCE DE LA DEMANDE DE BREVET A ETE REPRISE

ST Notification of lapse

Effective date: 20110531